Dr. Hutchins was most recently Chief Science and Chief Operating Officer at Heat Biologics (Nasdaq: HTBX) where he guided a focus on cancer and infectious disease directed therapies that activate the human immune system. Prior to joining Heat, Dr. Hutchins served as Vice President of Preclinical Research at Peregrine Pharmaceuticals, Inc., a biopharmaceutical company developing therapeutics to fight cancer and infectious diseases. Dr. Hutchins also served as Vice President, Preclinical Development at Inhibitex, Inc., which was acquired by Bristol-Myers Squibb. Earlier, Dr. Hutchins held several senior scientist positions in discovery research at Burroughs Wellcome and Glaxo Wellcome, with a visiting professor appointment at Rush Medical College.
Dr. Hutchins earned a B.S. in Biology from Oral Roberts University, a Ph.D. in Biomedical Sciences from the University of Texas, Health Science Center at the M.D. Anderson Cancer Center, and conducted postdoctoral training at the University of Southern California’s Department of Microbiology at the Norris Cancer Center. Dr. Hutchins’ publications and patents span the fields of oncology, infectious disease, osteoarthritis and immunology.
Current role
Chief Development Officer (cdo) at Boys & Girls Clubs of Southern Nevada
Chief Development Officer (cdo) at Helm.ai
Chief Development Officer (cdo) at Wyndham Hotels & Resorts
Chief Development Officer at Green Street Power Partners
EVP & Chief Development Officer at Macerich
Access the worlds's biggest network of public org charts
Learn more